Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.31 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2295307 | 0.82 | ALDH1A1 (0.42) | ALOX15 | |
| SCHEMBL17882031 | 0.78 | HCAR2 (0.36) | CYP4F2CYP4A11 | |
| SCHEMBL11164403 | 0.77 | — | — | |
| SCHEMBL17860704 | 0.75 | ALDH1A1 (0.48) | — | |
| SCHEMBL17860719 | 0.75 | ABCB11 (0.30) | — | |
| SCHEMBL2285823 | 0.75 | — | — | |
| SCHEMBL2289682 | 0.74 | SMN1; SMN2 (0.44) | ALOX15 | |
| SCHEMBL17454 | 0.74 | SMN1; SMN2 (0.40) | ALOX15CYP4F2CYP4A11 | |
| SCHEMBL1161503 | 0.74 | CYP1A2 (0.42) | ALOX15 | |
| SCHEMBL15114429 | 0.74 | SMN1; SMN2 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115697969-A | 7-or 8-hydroxy-isoquinoline and 7-or 8-hydroxy-quinoline derivatives as alpha-1 antitrypsin modulators for the treatment of alpha-1 antitrypsin deficiency (AATD) | 弗特克斯药品有限公司 | 2023-02-03 | — | — | CN | disclosed |
| EP-2346871-A1 | ALPHA HELIX MIMETICS IN THE TREATMENT OF CANCER | PRISM BioLab Corporation (JP) | 2011-07-27 | — | — | EP | disclosed |
| WO-2010044485-A1 | ALPHA HELIX MIMETICS IN THE TREATMENT OF CANCER | PRISM BIOLAB CORPORATION (JP) | 2010-04-22 | — | — | WO | disclosed |